Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Jennifer Ann Johnson, M.D.

Concepts

This page shows the publications Jennifer Johnson has written about HIV-1.
Connection Strength

0.213
  1. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 07 13; 218(4):633-644.
    View in: PubMed
    Score: 0.054
  2. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15; 211(4):518-28.
    View in: PubMed
    Score: 0.041
  3. First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). J Infect Dis. 2014 Oct 01; 210(7):1052-61.
    View in: PubMed
    Score: 0.040
  4. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 2013 Jan 15; 207(2):240-7.
    View in: PubMed
    Score: 0.036
  5. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7.
    View in: PubMed
    Score: 0.032
  6. Propionibacterium acnes brain abscess in a patient with HIV-1 infection. J Neurovirol. 2012 Apr; 18(2):148-50.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.